Top Markets
Coin of the day
Allena Pharmaceuticals, Inc. Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc.

ALNAQ
Rank in Stocks #42825
Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on... Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies. These treatments are devised to assist patients in the United States afflicted by uncommon and serious metabolic as well as renal conditions. Central to its pipeline is ALLN-346, an innovative enzyme designed to degrade urate, targeting hyperuricemia and gout in individuals with advanced chronic kidney disease. The company, which commenced operations in 2011 and has its main office in Newton, Massachusetts, made headlines on September 2, 2022, by seeking voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Share Price
$0.000001
Last synced: 2023-12-13
Market Cap
$23.51
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Allena Pharmaceuticals, Inc. (ALNAQ)

Category

P/S ratio for Allena Pharmaceuticals, Inc. (ALNAQ)
P/S ratio as of 2026 TTM: 0
According to Allena Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Allena Pharmaceuticals, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR